A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms SMAII
Most Recent Events
- 20 Sep 2024 Status changed from active, no longer recruiting to completed.
- 26 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2023 Planned End Date changed from 25 Feb 2025 to 25 Aug 2025.